MAGEB17: A Potential Drug Target for Melanoma (G645864)

Target Name: MAGEB17

NCBI ID: G645864

MAGEB17

Other Name(s): melanoma antigen family B17 | Melanoma-associated antigen B17 | MAGBH_HUMAN | MAGE family member B17 | melanoma antigen family B, 17 (pseudogene)

MAGEB17: A Potential Drug Target for Melanoma

Melanoma is a deadly form of skin cancer that ranks as the most common cause of cancer death in the United States. Despite advances in treatment, the survival rate for melanoma remains low, with a five-year survival rate of only 15%. The high mortality rate is largely due to the limited number of effective treatment options available for advanced stages of melanoma.

One potential solution to this problem is targeting MAGEB17, a protein that is expressed in high levels in melanoma cells. MAGEB17 is part of the melanoma antigen family (MAAF), which includes several proteins that have been identified as potential drug targets for melanoma.

The MAGEB17 protein is a 17-kDa transmembrane protein that is expressed in various tissues, including the skin, hair, and eyes. It is a member of the superfamily of cytoplasmic granules (SPG), which are a type of protein that are involved in various cellular processes, including intracellular signaling.

MAGEB17 has been shown to play a role in cell signaling and is involved in several signaling pathways that are involved in cancer progression. For example, MAGEB17 has been shown to be involved in the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation.

In addition to its role in cell signaling, MAGEB17 has also been shown to be involved in the development of cancer. For example, studies have shown that MAGEB17 is involved in the development of melanoma in animal models, and that it is expressed in human melanoma tumors.

Given the potential role of MAGEB17 in cancer progression and the high mortality rate for melanoma, it is a promising target for drug development. Several studies have shown that targeting MAGEB17 with small molecules or antibodies can result in the inhibition of melanoma growth and the regression of established melanoma tumors.

One of the challenges in targeting MAGEB17 is its high expression level in various tissues, which makes it difficult to target with small molecules or antibodies. However, researchers have shown that it is possible to target MAGEB17 specifically by using antibodies that are designed to recognize and selectively bind to the protein.

Another approach to targeting MAGEB17 is by using small molecules that can inhibit its function in cell signaling. Several studies have shown that inhibitors of MAGEB17 have been effective in inhibiting melanoma growth and regression in animal models. These inhibitors have been shown to act by inhibiting the activity of MAGEB17 in cell signaling pathways, such as the PI3K/Akt signaling pathway.

While the development of targeted therapies for melanoma is an promising direction, there are also concerns about the potential side effects and toxicity of these therapies. However, researchers are working to address these concerns by developing drugs that are designed to be safe and effective.

In conclusion, MAGEB17 is a promising target for drug development in melanoma. The protein's high expression level and involvement in cell signaling pathways make it an attractive target for small molecules or antibodies that can inhibit its function. While the development of targeted therapies for melanoma is still in its early stages, it holds great promise as a treatment for this deadly form of skin cancer.

Protein Name: MAGE Family Member B17

The "MAGEB17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEB17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets